Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 1/20 | 0.59 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | HTR1A | P08908 | 14/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 14/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2317607 | 0.89 | KDM4C (0.48) | NPC1RAB9AKDM4CMEN1KMT2A | |
| SCHEMBL6400656 | 0.88 | NPC1 (0.50) | NPC1RAB9AKDM4CMEN1KMT2A | |
| SCHEMBL12963637 | 0.82 | NPC1 (0.47) | NPC1RAB9AKDM4CMEN1KMT2A | |
| SCHEMBL875673 | 0.82 | L3MBTL1 (0.57) | NPC1RAB9AKDM4CMEN1KMT2A | |
| SCHEMBL27263264 | 0.82 | KDM4C (0.46) | NPC1RAB9AKDM4CMEN1KMT2A | |
| SCHEMBL772902 | 0.79 | KDM4C (0.53) | NPC1RAB9AKDM4CMEN1KMT2A | |
| SCHEMBL6402719 | 0.79 | NPC1 (0.53) | NPC1RAB9AKDM4CMEN1KMT2A | |
| SCHEMBL21591631 | 0.79 | NPC1 (0.52) | NPC1RAB9AKDM4CMEN1KMT2A | |
| SCHEMBL6947486 | 0.78 | NPC1 (0.52) | NPC1RAB9AKDM4CMEN1KMT2A | |
| SCHEMBL20906593 | 0.78 | NPC1 (0.48) | NPC1RAB9AKDM4CMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050171354-A1 | Piperidinylaminomethyl trifluoromethyl cyclic ether compounds as substance P antagonists | PFIZER INC. (US) | 2005-08-04 | — | — | US | disclosed |
| US-20030208079-A1 | Piperidinylaminomethyl trifluoromethyl cyclic ether compounds as substance P antagonists | PFIZER INC. | 2003-11-06 | — | — | US | disclosed |
| EP-1178984-B1 | 1-TRIFLUOROMETHYL-4-HYDROXY-7-PIPERIDINYL-AMINOMETHYLCHROMAN DERIVATIVES | PFIZER PROD INC (US) | 2003-03-19 | — | — | EP | disclosed |
| EP-1032571-B1 | PIPERIDINYLAMINOMETHYL TRIFLUOROMETHYL CYCLIC ETHER COMPOUNDS AS SUBSTANCE P ANTAGONISTS | PFIZER (US) | 2002-06-12 | — | — | EP | disclosed |
| EP-1178984-A2 | 1-TRIFLUOROMETHYL-4-HYDROXY-7-PIPERIDINYL-AMINOMETHYLCHROMAN DERIVATIVES | Pfizer Products Inc. (US) | 2002-02-13 | — | — | EP | disclosed |
| US-6239147-B1 | TO TREAT CNS, GASTROINTESTINAL AND OTHER DISORDERS. SUBSTANCE P ANTAGONISTS HAVING IMPROVED ACTIVITY AND FEWER SIDE EFFECTS, TREATMENT OF EMESIS INDUCED BY ANTINEOPLASTIC AGENTS, ISOCHROMAN RING | PFIZER INC | 2001-05-29 | — | — | US | disclosed |
| WO-2000071538-A2 | 1-TRIFLUOROMETHYL-4-HYDROXY-7-PIPERIDINYL-AMINOMETHYLCHROMAN DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2000-11-30 | — | — | WO | disclosed |
| EP-1032571-A1 | PIPERIDINYLAMINOMETHYL TRIFLUOROMETHYL CYCLIC ETHER COMPOUNDS AS SUBSTANCE P ANTAGONISTS | PFIZER INC. (US) | 2000-09-06 | — | — | EP | disclosed |
| WO-1999025714-A1 | PIPERIDINYLAMINOMETHYL TRIFLUOROMETHYL CYCLIC ETHER COMPOUNDS AS SUBSTANCE P ANTAGONISTS | PFIZER PHARMACEUTICALS INC. (JP) | 1999-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171354-A1 | Piperidinylaminomethyl trifluoromethyl cyclic ether compounds as substance P antagonists | HRH2, TACR1, HRH4 | NPC1 2100/4885RAB9A 2264/4885KDM4C 3413/4885 |
| US-20030208079-A1 | Piperidinylaminomethyl trifluoromethyl cyclic ether compounds as substance P antagonists | TACR1, HRH2, GRPR | NPC1 1630/4885RAB9A 2593/4885KDM4C 2892/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.